E. Klein

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 586 citations

Metabolic Syndrome, Diabetes Management, Cardiovascular Disease +9

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes

Lawrence Blonde, E. Klein, J. Han et al. · Diabetes Obesity and Metabolism · 2006 · 417 citations · Full text

Prediction of Antidepressant Effects of Sleep Deprivation by Metabolic Rates in the Ventral Anterior Cingulate and Medial Prefrontal Cortex

Joseph C. Wu, Monte S. Buchsbaum, J. Christian Gillin et al. · American Journal of Psychiatry · 1999 · 326 citations

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al. · The Lancet Diabetes & Endocrinology · 2019 · 317 citations · Full text

Diabetes Management, Urology, Medicine +11

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

Julio Rosenstock, Carlos A. Aguilar‐Salinas, E. Klein et al. · Current Medical Research and Opinion · 2009 · 286 citations